Diffuse, Large B-Cell, Lymphoma Clinical Trial
Official title:
An Open-label, Single-arm Phase II Study in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) to Evaluate Efficacy and Safety of Treatment With Single Agent Copanlisib and the Impact of Biomarkers Thereupon.
To assess the potential efficacy (in terms of objective response) of single agent copanlisib in patients with relapsed or refractory Diffuse large B-cell lymphoma (DLBCL) and assess the relationship between efficacy and a potentially predictive biomarker
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02871869 -
Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma
|
Phase 2/Phase 3 | |
| Completed |
NCT01848132 -
Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.
|
Phase 2 | |
| Terminated |
NCT02374424 -
Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory DLBCL Patients
|
Phase 2 | |
| Terminated |
NCT04236141 -
A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).
|
Phase 3 | |
| Completed |
NCT00599170 -
Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
|
Phase 2 | |
| Completed |
NCT02867566 -
A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients
|
Phase 3 | |
| Terminated |
NCT02855359 -
Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
|
Phase 2 | |
| Completed |
NCT02216890 -
Safety Study of SGN-CD70A in Cancer Patients
|
Phase 1 | |
| Active, not recruiting |
NCT01181271 -
Tandem Auto-Allo Transplant for Lymphoma
|
Phase 2 |